302440:KRXSK bioscience Co.,Ltd. Analysis
Data as of 2026-09-13 - not real-time
₩37,250.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
The moving-average structure behind SK bioscience Co.,Ltd. is neutral at KRW 37,250.00, with no clear ordering between short and long averages. It has gained 12.4% over the past 30 days. Relative strength is 50.1 — neutral — and the MACD signal is bearish. Recent trading has carved out support near KRW 35,100.00 and resistance around KRW 39,150.00.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 12.8% below the current quote. Revenue is contracting at 3.8% on a -12.8% profit margin.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 35.6%, a beta of 0.78 and a maximum drawdown of 45.9%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: sell, at a conviction of 7 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 12.8% below the current quote. Revenue is contracting at 3.8% on a -12.8% profit margin.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 35.6%, a beta of 0.78 and a maximum drawdown of 45.9%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: sell, at a conviction of 7 out of 10.
Top Market Events
SK Bioscience starts the week without fresh price-moving news, but with investors watching its vacciSouth Korea-based SK Bioscience Co Ltd is on investors' radar after agreeing to transfer its SKYVari
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Trading below the 200-day average of 43232.00
- MACD momentum is negative
- 30-day price change of +12.4%
Medium Term
1–3 yearsCautious
Model confidence: 6/10
Key Factors
- Trading below the 200-day average of 43232.00
- Analyst targets imply -12.8% versus the current price
- MACD momentum is negative
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Negative profit margin of -12.8%
- Analyst targets imply -12.8% versus the current price
- Negative return on equity of -4.2%
Key Metrics & Analysis
Financial Health
Revenue Growth-3.80%
Profit Margin-12.85%
P/E Ratio-38.5
ROE-4.25%
ROA-2.81%
Debt/Equity27.07
Op. Cash Flow₩4.5B
Free Cash Flow₩-281675726848
Industry P/E29.5
Technical Analysis
TrendNeutral
RSI50.1
Support₩35,100.00
Resistance₩39,150.00
MA 20₩37,615.00
MA 50₩36,325.00
MA 200₩43,232.00
MACDBearish
VolumeDecreasing
Fear & Greed Index93.14
Valuation
Fair Value₩4,179.11
Target Price₩32,500.00
Upside/Downside-12.75%
GradeOvervalued
TypeBlend
Risk Assessment
Beta0.78
Volatility35.62%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.